RT Journal Article
SR Electronic
T1 The responsiveness and validity of the CAMPHOR Utility Index
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1513
OP 1519
DO 10.1183/09031936.00069708
VO 32
IS 6
A1 D. M. Meads
A1 S. P. McKenna
A1 N. Doughty
A1 C. Das
A1 W. Gin-Sing
A1 J. Langley
A1 J. Pepke-Zaba
YR 2008
UL http://erj.ersjournals.com/content/32/6/1513.abstract
AB The aim of the present study was to validate and determine the mininal important difference (MID) and responsiveness of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Utility Index, a new tool enabling cost utility analyses. CAMPHOR, 6-min walking test (6MWT) and New York Heart Association (NYHA) data for 869 pulmonary hypertension patients (545 (63%) female; mean±sd age 56.6±15.4 yrs) from three centres were analysed. Utility was correlated with 6MWT data and calculated by NYHA class to assess validity. Effect sizes were calculated for those with two CAMPHOR assessments. Distribution and anchor-based MIDs were calculated. Analyses were carried out in patients receiving bosentan in order to determine whether or not those remaining in NYHA class III following treatment improved. The Utility Index distinguished between adjacent NYHA classes and correlated with 6MWT results. CAMPHOR subscales and utility were as responsive as the 6MWT (effect sizes ranged 0.31–0.69 for the CAMPHOR and 0.16–0.34 for the 6MWT). The within-group MID for the Utility Index was estimated to be ∼0.09. Patients remaining in NYHA class III experienced, on average, a significant improvement (CAMPHOR Utility Index and functioning), which exceeded the MID. The CAMPHOR Utility Index is valid and responsive to change. Patients can experience significant and important improvements even if they do not improve on the basis of traditional outcomes, such as NYHA functional class.